| Added by | mollevi |
|---|---|
| Group name | EquipeCG |
| Item Type | Note |
| Note | The following values have no corresponding Zotero field: auth-address: Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA. david.westover@roswellpark.org. Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA. xiang.ling@roswellpark.org. Canget BioTekpharma, LLC, Buffalo, NY, 14203, USA. xiang.ling@roswellpark.org. Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA. yhlam1992@gmail.com. Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA. welch11@canisius.edu. Center for Drug Discovery, RTI International, Research Triangle Park, NC, 27709, USA. cjin@rti.org. IRCM, Institut de Recherche en Cancerologie de Montpellier; INSERM, U896; Universite Montpellier1; Institut regional du Cancer Montpellier, F-34298, Montpellier, France. celine.gongora@inserm.fr. IRCM, Institut de Recherche en Cancerologie de Montpellier; INSERM, U896; Universite Montpellier1; Institut regional du Cancer Montpellier, F-34298, Montpellier, France. maguy.delrio@icm.unicancer.fr. Center for Drug Discovery, RTI International, Research Triangle Park, NC, 27709, USA. durhamwani@earthlink.net. Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA. fengzhi.li@roswellpark.org. alt-title: Molecular cancer accession-num: 25928015 |
| Tags | _EndnoteXML import |
| Date Added | 2018/07/20 - 10:05:58 |
| Date Modified | 2018/07/20 - 10:05:58 |
| Parent item | FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance |
Institut de Recherche en Cancérologie de
